Studies on the removal of a bovine spongiform encephalopathy‐derived agent by processes used in the manufacture of human immunoglobulin

Vox Sanguinis - Tập 83 Số 2 - Trang 137-145 - 2002
H. Reichl1, Peter R. Foster2, Anne G. Welch2, Q. Li2, Ian MacGregor2, R. A. Somerville3, K. Fernie3, Philip Steele3, D. M. Taylor3
1Haemosan Life Science Services GmbH, Vienna, Austria
2Scottish National Blood Transfusion Service, Edinburgh, UK
3Neuropathogenesis Unit, Institute for Animal Health, Edinburgh, UK

Tóm tắt

Background and Objectives There is still uncertainty over how the agent of variant Creutzfeld‐Jakob disease (vCJD) would partition during the manufacture of plasma derivatives. In this study, a BSE‐derived agent was used as a vCJD model to determine the extent to which infectivity could be removed by selected steps used in the manufacture of intravenous immunoglobulin (IVIG).Materials and Methods Murine‐passaged BSE (strain 301V), in the form of a microsomal fraction prepared from infected brain, was used to ‘spike’ the starting material in three experiments. The partitioning of BSE infectivity was measured over Fraction I+III precipitation, borosilicate microfibre depth filtration and Seitz depth filtration, with these steps being examined individually and in series.Results Most 301V infectivity partitioned into Fraction I+III (log reduction 2·1). Infectivity remaining in Supernatant I+III was reduced by AP20 glass‐fibre depth filtration (log reduction 0·6) and subsequently removed to below the limit of detection by Seitz KS80 depth filtration, giving an overall log reduction of ≥ 2·9 for the three steps in series. By contrast, glass‐fibre depth filtration gave a log reduction of 2·4 when challenged directly with ‘spiked’ feedstock. Seitz KS80 depth filtration gave a log reduction of ≥ 3·1 when challenged directly with ‘spiked’ feedstock and also removed residual infectivity to below the limit of detection when applied as the final step in series.Conclusions Results using a BSE‐derived agent suggest that vCJD infectivity should be substantially removed from immunoglobulin G (IgG) solutions by Fraction I+III precipitation and Seitz KS80 depth filtration. The three different process steps examined acted in a complementary manner to one another when operated in series. However, the data demonstrated that it would be inappropriate to add together the reduction factors that had been derived for each step in isolation.

Từ khóa


Tài liệu tham khảo

10.1136/vr.121.18.419

BraakmanJL:BSE in Europe 7 December2001.http://www.ourworld.cs.com/jlbraakman/BSE.htm

10.1016/S0140-6736(96)91412-9

10.1038/38925

10.1038/39057

10.1136/bmj.322.7290.841

Department of Health, 2002, Monthly Creutzfeldt–Jakob Disease Statistics.

Institute de Veille Sanitaire:, 2002, Nombre de Cas de Maladie Creutzfeldt‐Jakob.

10.1212/WNL.55.8.1075

10.1002/(SICI)1098-1101(1999)14:3<135::AID-JCA6>3.0.CO;2-S

10.1016/S0140-6736(97)24002-X

10.1016/S0140-6736(98)12075-5

10.3109/07853890009002026

10.1046/j.1365-2516.2002.00618.x

Det Norske Veritas:, 1999, Assessment of the Risk of Exposure to vCJD Infectivity in Blood and Blood Products.

10.1046/j.1537-2995.1998.38998408999.x

10.1046/j.1537-2995.1999.39111169.x

10.1046/j.1423-0410.2000.7820086.x

10.1016/S0166-0934(99)00135-4

10.1046/j.1537-2995.2001.41040449.x

10.1016/0021-9975(71)90100-9

10.1016/0021-9975(68)90005-4

10.1385/0-89603-342-2:223

Dougherty R, 1964, Techniques in Experimental Virology, 169

10.1099/0022-1317-77-8-1941

Stenland CJ, 2001, Tracking partitioning of the pathogenic form of the human prion protein during plasma fractionation using a sensitive Western blot assay, Thromb Haemost, 86, P2606

10.1073/pnas.96.26.15137

10.1073/pnas.041490898

10.1098/rstb.1994.0036

10.1053/jhin.2000.0790

10.1099/0022-1317-67-2-255

Morgenthaler JJ, 1998, Proceedings of Cambridge Healthtech Institute Conference, ‘TSE Issues’

Thông tin
Thông tin xuất bản

Vox Sanguinis

Tập 83 Số 2

137-145

Thông tin tác giả